Company profile
ANNEXON, INC.
NASDAQ:ANNXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TANRUPRUBART | phase3 | — | 7 | active |
| VONAPRUMENT | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (16)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04035135 | phase1 | completed | 2020-01-29 | 2021-05-19 | Annexon, Inc. | A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) |
| NCT04535752 | phase1 | completed | 2020-10-30 | 2021-06-26 | Annexon, Inc. | A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV) |
| NCT06510816 | phase3 | active_not_recruiting | 2024-07-30 | 2027-07-31 | Annexon, Inc. | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) |
| NCT04656561 | phase2 | completed | 2021-02-26 | 2023-03-28 | Annexon, Inc. | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy |
| NCT05780515 | phase1 | completed | 2022-08-09 | 2023-08-31 | Annexon, Inc. | A Study of ANX009 in Adult Participants With Lupus Nephritis |
FDA applications (0)
No records yet.